Lucid Diagnostics Inc. announced that it has entered into subscription agreements and exchange agreements with certain accredited investors, which agreements provided for the sale to the Series B Investors of 12,495 shares of the Company?s newly designated Series B Convertible Preferred Stock, par value $0.001 per share at a purchase price of $1,000 per share for the gross proceeds of $12,495,000; the exchange by the Series B Investors of 13,625 shares of the Company?s Series A Convertible Preferred Stock, par value $0.001 per share and 10,670 shares of the Company?s Series A-1 Convertible Preferred Stock, par value $0.001 per share held by them for 31,790 shares of Series B Preferred Stock for the aggregate gross proceeds of $18,160,000 on March 13, 2024. Each share of Series B Preferred Stock is convertible at the option of the holder, from and after the six-month anniversary of its issuance, subject to the beneficial ownership and primary market limitations into such number of shares of the Company?s common stock, par value $0.001 per share as is equal to the number of shares of Series B Preferred Stock to be converted, multiplied by the stated value of $1,000 divided by the conversion price in effect at the time of the conversion. The initial conversion price will be $1.2444, subject to adjustment in the event of stock splits, stock dividends, and similar transactions.